abs372.txt	purpose	standard	frontline	treatment	of	patients	with	metastatic	renal	cellcarcinoma	currently	includes	sunitinib		a	barrier	to	long-term	withsunitinib	the	development	significant	adverse	effects	includingdiarrhea	hand-foot	syndrome	(hfs)	and	fatigue	this	trial	assessed	effectof	an	alternate	2	weeks	on	1	week	off	(2/1)	schedule	toxicityand	efficacy	in	previously	untreated	methods	started	oral	administration	50	mg	sunitinibon	2/1	underwent	dose	alterations	if	toxicitydeveloped	primary	end	point	was	<	15%	grade	â‰¥	3	diarrhea	or	hfs	60	upper	bound	ci	would	fall	below	published	4/2schedule	toxicity	rate	25%	30%	results	fifty-nine	weretreated	between	august	2014	march	2016	seventy-seven	percent	wereintermediate	poor	risk	per	memorial	sloan	kettering	cancer	center	criteria	median	follow-up	17	months	experienced	3fatigue	37%	required	reduction	10%	discontinuedbecause	overall	response	57%	progression-freesurvival	13	7	survival	not	reached	at	12weeks	functional	assessment	therapy-general	scores	dropped	0%and	from	baseline	less	who	continued	treatmentlonger	conclusion	decreased	notmet	however	is	associated	lackof	4	low	patient	discontinuation	high
